BR112012011463A2 - uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla. - Google Patents

uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.

Info

Publication number
BR112012011463A2
BR112012011463A2 BR112012011463A BR112012011463A BR112012011463A2 BR 112012011463 A2 BR112012011463 A2 BR 112012011463A2 BR 112012011463 A BR112012011463 A BR 112012011463A BR 112012011463 A BR112012011463 A BR 112012011463A BR 112012011463 A2 BR112012011463 A2 BR 112012011463A2
Authority
BR
Brazil
Prior art keywords
populations
predict
antibodies
efficacy
multiple sclerosis
Prior art date
Application number
BR112012011463A
Other languages
English (en)
Inventor
Peter Sheridan James Iii
Original Assignee
Abbott Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp
Publication of BR112012011463A2 publication Critical patent/BR112012011463A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
BR112012011463A 2009-10-30 2010-10-29 uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla. BR112012011463A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25676109P 2009-10-30 2009-10-30
PCT/US2010/054699 WO2011053777A1 (en) 2009-10-30 2010-10-29 Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
BR112012011463A2 true BR112012011463A2 (pt) 2017-05-02

Family

ID=43242330

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011463A BR112012011463A2 (pt) 2009-10-30 2010-10-29 uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.

Country Status (6)

Country Link
US (1) US20110104153A1 (pt)
EP (1) EP2470901A1 (pt)
AU (1) AU2010313318A1 (pt)
BR (1) BR112012011463A2 (pt)
CA (1) CA2774286A1 (pt)
WO (1) WO2011053777A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012309824A1 (en) 2011-09-12 2013-04-18 Abbvie Biotherapeutics Inc. Artificial NK cells and uses thereof
CN113416700B (zh) * 2021-07-09 2023-04-11 天晴干细胞股份有限公司 一种高效的因子分泌型nk细胞扩增方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5336489A (en) 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5152980A (en) 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5571507A (en) 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
US20100273204A1 (en) * 2009-04-27 2010-10-28 Facet Biotech Corporation Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients

Also Published As

Publication number Publication date
US20110104153A1 (en) 2011-05-05
WO2011053777A1 (en) 2011-05-05
EP2470901A1 (en) 2012-07-04
AU2010313318A1 (en) 2012-04-12
CA2774286A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
SMT201600218B (it) Batterio per uso come probiotico per applicazioni nutrizionali e mediche
BR112013014448A2 (pt) célula combustível redox, e, solução de católito para uso em uma célula combustível redox
CL2012003385A1 (es) Tratamiento para la incontinencia.
BR112013018953A2 (pt) composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais.
CO6650338A2 (es) Antígenos de tuberculosis modificados
IT1400425B1 (it) Modified snrnas for use in therapy.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
BRPI0924535A2 (pt) Anticorpo de duplo direcionamento de nova forma, e uso do mesmmo
BRPI0922296A2 (pt) Composições para o uso em recém-nascidos com baixo peso no nascimento.
IL223014B (en) A sterile liquid formulation having an absolute viscosity of 10 cp or less, a method for reducing the viscosity of a protein formulation, and using the formulation in an amount effective for treatment
EA201400579A1 (ru) Антитела к il-36r
CA144355S (en) Chair
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
BR112014015297A8 (pt) processamento de biomassa para uso em células de combustável
BR112013001875A2 (pt) cueca masculina com espaço separado para o pênis
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
BR112014016243A8 (pt) apoio de braço, em particular para uso em cadeiras de escritório
ECSP13012446A (es) Ligandos fosfina para reacciones catalíticas
BR112014007150A2 (pt) artigos abrasivos de redução de ruído
GT201200015S (es) Diseño de golosina para mascotas.
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
BR112012011463A2 (pt) uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
DK2446780T3 (da) Stol, især kontorstol

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]